Sai Life Sciences commenced commercial operations at the second phase of its Unit IV facility in Bidar, Karnataka, marking a major milestone in its capacity expansion strategy. This phase contributes approximately 91 kilolitres (kL) of new production capacity, fulfilling the company’s planned addition of around 195 kL as detailed in its prospectus.
Enhanced Production Capacity to Support Global Demand
With the latest expansion, the total installed capacity at unit IV has reached approximately 640 kL. The upgraded facility is equipped to manufacture registered starting materials (RSMs), intermediates, and active pharmaceutical ingredients (APIs) for both clinical trials and commercial supply. The development strengthens the company’s ability to meet rising global demand and reinforces its position in the pharmaceutical supply chain.
Boosting Capabilities Across Drug Development
The expansion aligns with Sai Life Sciences’ commitment to providing end-to-end solutions for pharmaceutical innovation. Headquartered in Hyderabad, the company operates as a leading global Contract Research, Development, and Manufacturing Organization (CRDMO). It partners with pharma and biotech companies to accelerate the discovery, development, and commercialization of novel therapeutics.
Integrated Services for Faster Drug Delivery
Sai Life Sciences offers a broad range of integrated services, including medicinal chemistry, process development, and scalable manufacturing. As reported by projectstoday.com, the Bidar facility demonstrates the company’s agility in scaling operations and delivering high-quality solutions to its global partners.
